{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:50:41Z","timestamp":1791435041875,"version":"4.3.3"},"update-to":[{"DOI":"10.1002\/14651858.cd013513.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000}}],"reference-count":210,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013513.pub3","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T10:41:32Z","timestamp":1615545692000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Biologics for chronic rhinosinusitis"],"prefix":"10.1002","volume":"2021","author":[{"given":"Lee-Yee","family":"Chong","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patorn","family":"Piromchai","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology; Faculty of Medicine, Khon Kaen University; Khon Kaen Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Sharp","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Excellence; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornkiat","family":"Snidvongs","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Faculty of Medicine; Chulalongkorn University; Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie E","family":"Webster","sequence":"additional","affiliation":[{"name":"Cochrane ENT; Nuffield Department of Surgical Sciences, University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Philpott","sequence":"additional","affiliation":[{"name":"Department of Medicine; Norwich Medical School, University of East Anglia; Norwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hopkins","sequence":"additional","affiliation":[{"name":"ENT Department; Guy's Hospital; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J","family":"Burton","sequence":"additional","affiliation":[{"name":"Cochrane UK; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"Suppl 60","key":"10.1002\/14651858.CD013513.pub3-BIB0001|cit1","first-page":"OA251","article-title":"Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: results from a phase 2a trial","volume":"48","author":"Bachert","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0002|cit2","first-page":"12","article-title":"Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis","volume":"71","author":"Bachert","year":"2019","journal-title":"Allergy"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"AB90","DOI":"10.1016\/j.jaci.2017.12.290","article-title":"Atopic comorbidities and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) who failed intranasal corticosteroids","volume":"141","author":"Bachert","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0005|cit5","first-page":"107","article-title":"Dupilumab in chronic sinusitis with nasal polyposis, with and without asthma","volume":"70","author":"Bachert","year":"2015","journal-title":"Allergy"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD013513.pub3-BIB0006|cit6","first-page":"PA5004","article-title":"Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSWNP)","volume":"52","author":"Bachert","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0007|cit7","unstructured":"An evaluation of dupilumab in patients with nasal polyposis and chronic symptoms of sinusitis http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-001803-35-BE"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0009|cit9","unstructured":"An evaluation of dupilumab in patients with nasal polyposis and chronic symptoms of sinusitis https:\/\/clinicaltrials.gov\/show\/NCT01920893"},{"issue":"7","key":"10.1002\/14651858.CD013513.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaoto.2016.0678","article-title":"Subcutaneous dupilumab and mometasone furoate nasal spray for chronic rhinosinusitis with polyps","volume":"142","author":"Schneider","year":"2016","journal-title":"JAMA Otolaryngology - Head and Neck Surgery"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0011|cit11","first-page":"S118","article-title":"The effect of dupilumab on biomarkers in the peripheral blood and nasal secretions in the treatment of chronic sinusitis with nasal polyposis","volume":"64","author":"Swanson","year":"2015","journal-title":"Inflammation Research"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0013|cit13","unstructured":"A two-part, randomised, double-blind, placebo controlled, multi-center study to investigate the use of mepolizumab (SB-240563) in reducing the need for surgery in subjects with severe bilateral nasal polyposis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-003772-21\/NL"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0014|cit14","unstructured":"A randomised, double-blind, placebo controlled, multi-center study to investigate the use of mepolizumab (Sb-240563) in reducing the need for surgery in subjects with severe bilateral nasal polyposis https:\/\/clinicaltrials.gov\/show\/nct01362244"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0016|cit16","unstructured":"Clinical and biological effects of anti-IgE (omalizumab) in patients with bilateral nasal polyposis and asthma http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-003524-11-BE"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"AB69","DOI":"10.1016\/j.jaci.2011.12.749","article-title":"Omalizumab is effective in allergic and non-allergic patients with nasal polyps and asthma","volume":"129","author":"Gevaert","year":"2012","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0019|cit19","unstructured":"Clinical and biological effects of anti-IgE (omalizumab) in patients with bilateral nasal polyposis and asthma https:\/\/clinicaltrials.gov\/show\/NCT01393340"},{"issue":"10209","key":"10.1002\/14651858.CD013513.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0021|cit21","unstructured":"Controlled clinical study of dupilumab in patients with nasal polyps https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-003101-42"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"AB422","DOI":"10.1016\/j.jaci.2018.12.948","article-title":"Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps: results from the randomized phase 3 sinus-24 study","volume":"143","author":"Han","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0023|cit23","unstructured":"A controlled clinical study of dupilumab in patients with bilateral nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT02912468"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"AB433","DOI":"10.1016\/j.jaci.2018.12.980","article-title":"A randomized phase 3 study, sinus-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps","volume":"143","author":"Bachert","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"10209","key":"10.1002\/14651858.CD013513.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD013513.pub3-BIB0026|cit26","first-page":"2447","article-title":"Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma","volume":"7","author":"Bachert","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology: In Practice"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0027|cit27","unstructured":"Controlled clinical study of dupilumab in patients with nasal polyps https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-001314-10"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0028|cit28","unstructured":"Controlled clinical study of dupilumab in patients with nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT02898454"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0029|cit29","unstructured":"Subcutaneous omalizumab for treatment of chronic rhinosinusitis with nasal polyposis https:\/\/clinicaltrials.gov\/show\/nct01066104 2009"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.jaci.2008.12.766","article-title":"A randomized, double-blind, placebo-controlled clinical trial of omalizumab for chronic rhinosinusitis","volume":"123","author":"Mehta","year":"2009","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0031|cit31","unstructured":"Xolair in patients with chronic sinusitis https:\/\/clinicaltrials.gov\/show\/NCT00117611 2005"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0033|cit33","unstructured":"A phase 3 clinical trial of omalizumab for chronic rhinosinusitis with nasal polyps https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001724-22\/GB"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.anai.2019.08.077","article-title":"Omalizumab efficacy and safety in nasal polyposis: results from two parallel, double-blind, placebo-controlled trials","volume":"123","author":"Gevaert","year":"2019","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub3-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/j.jval.2020.04.1329","article-title":"PRS2 Proportion of patients with nasal polyposis achieving clinically important improvements in quality of life with omalizumab treatment","volume":"23","author":"Lee","year":"2020","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0037|cit37","unstructured":"A clinical trial of omalizumab in participants with chronic rhinosinusitis with nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT03280550"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0038|cit38","unstructured":"A phase 3 clinical trial of omalizumab for chronic rhinosinusitis with nasal polyps https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001718-28\/BE"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.anai.2019.08.077","article-title":"Omalizumab efficacy and safety in nasal polyposis: results from two parallel, double-blind, placebo-controlled trials","volume":"123","author":"Gevaert","year":"2019","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub3-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/j.jval.2020.04.1329","article-title":"PRS2 Proportion of patients with nasal polyposis achieving clinically important improvements in quality of life with omalizumab treatment","volume":"23","author":"Lee","year":"2020","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0042|cit42","unstructured":"A clinical trial of omalizumab in participants with chronic rhinosinusitis with nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT03280537"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0043|cit43","first-page":"A4274","article-title":"Exacerbation reduction and early and sustained improvements in SGRQ, lung function, and symptoms of nasal polyposis with benralizumab for severe, eosinophilic asthma: phase IIIb ANDHI trial","volume":"201","author":"Harrison","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0044|cit44","unstructured":"A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma https:\/\/clinicaltrials.gov\/show\/NCT03170271"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"AB149","DOI":"10.1016\/j.jaci.2019.12.480","article-title":"Omalizumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of asthma status","volume":"145","author":"Bachert","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"A9","DOI":"10.1016\/j.chest.2020.05.010","article-title":"Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis","volume":"157","author":"Bagnasco","year":"2020","journal-title":"Chest"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"AB123","DOI":"10.1016\/j.jaci.2018.12.373","article-title":"Dupilumab improves outcomes of concurrent asthma and chronic sino-nasal conditions in patients with atopic dermatitis-a pooled analysis of four phase 3 studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFE)","volume":"143","author":"Boguniewicz","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"10","key":"10.1002\/14651858.CD013513.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"AB84","DOI":"10.1016\/j.jaci.2010.12.340","article-title":"Efficacy of reslizumab in patients with poorly controlled eosinophilic asthma: subgroup analysis of patients with nasal polyps [Abstract]","volume":"127","author":"Mathur","year":"2011","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0050|cit50","first-page":"1714","article-title":"Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps","volume":"8","author":"Chan","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology: in Practice"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0051|cit51","unstructured":"Efficacy of omalizumab in patients with chronic sinusitis and nasal polyps combined with asthma http:\/\/www.chictr.org.cn\/showproj.aspx?proj=40553"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"AB250","DOI":"10.1016\/j.jaci.2019.12.108","article-title":"Omalizumab improves quality of life in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma","volume":"145","author":"Corren","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0053|cit53","first-page":"442","article-title":"Comparison of different medical treatment options for CRSwNP: doxycycline, methylprednisolone, mepolizumab and omalizumab","volume":"70","author":"De Schryver","year":"2015","journal-title":"Allergy"},{"issue":"Suppl 106","key":"10.1002\/14651858.CD013513.pub3-BIB0054|cit54","first-page":"330","article-title":"Dupilumab reduces need for systemic corticosteroid use, sinonasal surgery in patients with severe chronic rhinosinusitis with nasal polyps: pooled results from the SINUS-24, SINUS-52 phase 3 studies","volume":"74","author":"Desrosiers","year":"2019","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.anai.2018.02.030","article-title":"Biologics","volume":"120","author":"Dinakar","year":"2018","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0056|cit56","unstructured":"A study of omalizumab in patients with chronic rhinosinusitis with nasal polyps https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-003450-16"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/j.jaci.2004.12.566","article-title":"Anti-interleukin-5 treatment in nasal polyposis","volume":"115","author":"Gevaert","year":"2005","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Gevaert P Van Zele T Stammberger H Staudinger H Tavernier J van Cauwenberge P Nasal interleukin-5 levels determine the response to anti-interleukin-5 treatment in nasal polyp patients 3rd EAACI Davos Meeting in Basic Immunology in Allergy and Clinical Immunology; 2005 February 3-6; Davos, Switzerland 2005","DOI":"10.1016\/j.jaci.2006.05.031"},{"issue":"2 (Suppl 1)","key":"10.1002\/14651858.CD013513.pub3-BIB0060|cit60","first-page":"Abstract No. L2","article-title":"Mepolizumab, a humanised anti-IL-5 monoclonal antibody, as treatment of severe nasal polyposis","volume":"121","author":"Gevaert","year":"2008","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1939-4551-7-S1-P9","article-title":"Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis","volume":"7","author":"Gonzalez-Diaz","year":"2014","journal-title":"World Allergy Organization Journal"},{"issue":"12","key":"10.1002\/14651858.CD013513.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin-hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease: a randomized trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013513.pub3-BIB0063|cit63","first-page":"PA3549","article-title":"Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial","volume":"50","author":"Hellings","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/resp.13268","article-title":"Dupilumab improves ACQ-5 items in CRSwNP patients with comorbid asthma","volume":"23","author":"Hellings","year":"2018","journal-title":"Respiratology"},{"issue":"7","key":"10.1002\/14651858.CD013513.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40265-020-01298-9","article-title":"Dupilumab: a review in chronic rhinosinusitis with nasal polyps","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"AB26","DOI":"10.1016\/j.jaci.2019.12.808","article-title":"Mepolizumab reduces exacerbations and improves health-related quality of life in patients with severe asthma and nasal polyps, sinusitis, or allergic rhinitis","volume":"145","author":"Jain","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.anai.2019.08.251","article-title":"Clinical efficacy characterization of benralizumab for patients with nasal polyposis and severe, uncontrolled eosinophilic asthma","volume":"123","author":"Katial","year":"2019","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"7","key":"10.1002\/14651858.CD013513.pub3-BIB0068|cit68","first-page":"2462","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology: In Practice"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0069|cit69","first-page":"A7356","article-title":"Dupilumab improves upper and lower airway outcome measures in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma: pooled results from the SINUS-24 and SINUS-52 phase 3 studies","volume":"199","author":"Laidlaw","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 63","key":"10.1002\/14651858.CD013513.pub3-BIB0070|cit70","first-page":"PA539","article-title":"Dupilumab (DPL) improves upper and lower airway outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP) with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD): pooled results from SINUS-24, SINUS-52 phase 3 trials","volume":"54","author":"Laidlaw","year":"2019","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0071|cit71","doi-asserted-by":"crossref","unstructured":"Laidlaw TM Mullol J Canonica GW Bachert C Han JK Lu X Dupilumab improves upper and lower airway outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP) with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD): pooled results from SINUS-24, SINUS-52 phase 3 trials Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 2020 4 Suppl 2 31 2","DOI":"10.1183\/13993003.congress-2019.PA539"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"AB101","DOI":"10.1016\/j.jaci.2018.12.307","article-title":"Dupilumab consistently improves rhinoconjunctivitis-specific health-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid allergic rhinitis: results from the phase 3 LIBERTY ASTHMA QUEST study","volume":"143","author":"Bousquet","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD013513.pub3-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"PA1125","DOI":"10.1183\/13993003.congress-2018.PA1125","article-title":"Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS\/NP) in LIBERTY ASTHMA QUEST","volume":"52","author":"Busse","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"AB97","DOI":"10.1016\/j.jaci.2018.12.296","article-title":"Dupilumab improves lung function and reduces severe exacerbation rate in patients with uncontrolled, moderate-to-severe asthma with or without comorbid allergic rhinitis: results from the phase 3 LIBERTY ASTHMA QUEST study","volume":"143","author":"Busse","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0076|cit76","first-page":"A6163","article-title":"Dupilumab treatment produces rapid and sustained improvements in FEV1 in patients with uncontrolled, moderate-to-severe asthma from the LIBERTY ASTHMA QUEST study","volume":"197","author":"Castro","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.anai.2018.09.021","article-title":"Dupilumab efficacy in uncontrolled, moderate-to-severe allergic asthma in the phase 3 LIBERTY ASTHMA QUEST study","volume":"121","author":"Castro","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"26","key":"10.1002\/14651858.CD013513.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0079|cit79","first-page":"A7700","article-title":"A randomized, controlled phase 3 study, LIBERTY ASTHMA QUEST, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma","volume":"197","author":"Castro","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013513.pub3-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"PA4081","DOI":"10.1183\/1393003.congress-2017.PA4018","article-title":"Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility","volume":"50","author":"Castro","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"AB97","DOI":"10.1016\/j.jaci.2018.12.297","article-title":"Dupilumab suppresses inflammatory biomarkers in asthma patients with or without allergic rhinitis: post hoc analysis of the LIBERTY ASTHMA QUEST study","volume":"143","author":"Corren","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.anai.2018.08.005","article-title":"Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma","volume":"122","author":"Corren","year":"2019","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0083|cit83","first-page":"A5948","article-title":"Dupilumab produces rapid and sustained improvements in asthma-related symptoms in patients with uncontrolled, moderate-to-severe asthma from the LIBERTY ASTHMA QUEST study","volume":"197","author":"Corren","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"A26","DOI":"10.1016\/j.chest.2017.08.056","article-title":"Dupilumab improves asthma control and asthma-related quality of life in uncontrolled persistent asthma patients across all baseline exacerbation rates","volume":"152","author":"Corren","year":"2017","journal-title":"Chest"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.anai.2018.09.136","article-title":"Dupilumab improves asthma control in patients with uncontrolled, moderate-to-severe asthma, regardless of exacerbation history","volume":"121","author":"Corren","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD013513.pub3-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"PA1124","DOI":"10.1183\/13993003.congress-2018.PA1124","article-title":"Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS\/NP) in liberty asthma quest","volume":"52","author":"Corren","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0087|cit87","first-page":"108","article-title":"Dupilumab efficacy in severe asthma exacerbations by different baseline patient characteristics in patients with uncontrolled persistent asthma","volume":"72","author":"Fabbri","year":"2017","journal-title":"Allergy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0088|cit88","first-page":"110","article-title":"Dupilumab improves asthma outcomes regardless of baseline lung function","volume":"24","author":"Katelaris","year":"2019","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013513.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/imj.58_13578","article-title":"Dupilumab efficacy and effect on asthma control in patients with uncontrolled persistent asthma and comorbid chronic rhinosinusitis with or without nasal polyps","volume":"47","author":"Katelaris","year":"2017","journal-title":"Internal Medicine Journal"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013513.pub3-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"PA3351","DOI":"10.1183\/1393003.congress-2017.PA3551","article-title":"Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis","volume":"50","author":"Katial","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"P04","DOI":"10.1055\/s-0039-1678039","article-title":"Dupilumab improved asthma control in patients with uncontrolled, moderate-to-severe asthma, regardless of exacerbations in the previous year","volume":"73","author":"Korn","year":"2019","journal-title":"Pneumologie (Stuttgart, Germany)"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0092|cit92","unstructured":"Maspero J Busse WW Katelaris CH Yanez A Guillonneau S Chen Z Dupilumab improves health related quality of life in uncontrolled, moderate-to-severe asthma patients with comorbid allergic rhinitis from the phase 3 LIBERTY ASTHMA QUEST study Allergy 2018 73 Suppl 105 30"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"AB98","DOI":"10.1016\/j.jaci.2018.12.299","article-title":"Dupilumab suppresses type 2 biomarkers in asthma patients with and without comorbid chronic rhinosinusitis with or without nasal polyposis (CRS\/NP): post hoc analysis of LIBERTY ASTHMA QUEST","volume":"143","author":"Maspero","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Maspero JF Katelaris C Jayawardena S Rowe P Maroni J Pirozzi G Dupilumab efficacy in uncontrolled persistent asthma patients with history of comorbid chronic rhinosinusitis with or without nasal polyps American Journal of Respiratory and Critical Care Medicine 2017 195","DOI":"10.1111\/imj.58_13578"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0095|cit95","unstructured":"Evaluation of dupilumab in patients with persistent asthma (LIBERTY ASTHMA QUEST) https:\/\/clinicaltrials.gov\/show\/nct02414854"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0096|cit96","first-page":"A121","article-title":"Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 LIBERTY ASTHMA QUEST study","volume":"73","author":"Pavord","year":"2018","journal-title":"Thorax"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013513.pub3-BIB0097|cit97","first-page":"463","article-title":"Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high-and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study","volume":"73","author":"Pavord","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD013513.pub3-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"OA1651","DOI":"10.1183\/13993003.congress-2018.OA1651","article-title":"Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS\/NP) in LIBERTY ASTHMA QUEST","volume":"52","author":"Pavord","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0099|cit99","first-page":"154","article-title":"Dupilumab improves FEV1 and exacerbations in asthma with allergic rhinitis","volume":"23","author":"Weinstein","year":"2018","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub3-BIB0100|cit100","first-page":"237","article-title":"Dupilumab improves sinonasal symptoms of perennial allergic rhinitis (PAR) in uncontrolled persistent asthma patients with comorbid PAR","volume":"38","author":"Weinstein","year":"2017","journal-title":"Allergy and Asthma Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma","volume":"142","author":"Weinstein","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD013513.pub3-BIB0102|cit102","first-page":"PA5005","article-title":"Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in LIBERTY ASTHMA QUEST","volume":"52","author":"Wenzel","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0103|cit103","first-page":"S69","article-title":"Semi-mechanistic pharmacokinetic\/pharmacodynamic (PK\/PD) modeling of dupilumab on pre-bronchodilator forced expiratory volume in 1 second (FEV1) in uncontrolled moderate-to-severe asthma","volume":"45","author":"Zhang","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"AB169","DOI":"10.1016\/j.jaci.2019.12.349","article-title":"Dupilumab treatment improves sense of smell in patients with chronic rhinosinusitis with nasal polyps - pooled results from the SINUS-24 and SINUS-52 phase 3 trials","volume":"145","author":"Mullol","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0105|cit105","unstructured":"Efficacy and safety study of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control https:\/\/clinicaltrials.gov\/show\/nct02281318"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013513.pub3-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"PA3583","DOI":"10.1183\/1393003.congress-2017.PA3583","article-title":"Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma","volume":"50","author":"Nelsen","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0107|cit107","first-page":"AB173","article-title":"Dupilumab as add-on therapy for aspirin-exacerbated respiratory disease (AERD)","volume":"145","author":"Mustafa","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0108|cit108","unstructured":"Mustafa SS Vadamalai K Scott B Ramsey A Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease American Journal of Rhinology & Allergy 10.1177\/1945892420961969 32967430"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"AB90","DOI":"10.1016\/j.jaci.2016.12.245","article-title":"Dupilumab improves sense of smell and reduces anosmia among patients with nasal polyposis and chronic sinusitis: results from a phase 2a trial","volume":"139","author":"Naclerio","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0110|cit110","unstructured":"Effects of anti-IgE antibody omalizumab on patients with chronic sinusitis https:\/\/clinicaltrials.gov\/show\/nct00603785"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0112|cit112","unstructured":"A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma https:\/\/clinicaltrials.gov\/show\/NCT01285323"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"AB86","DOI":"10.1016\/j.jaci.2015.12.409","article-title":"Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils","volume":"137","author":"Weinstein","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"Journal of Allergy & Clinical Immunology in Practice"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0115|cit115","unstructured":"A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 282 in healthy subjects and subjects with chronic rhinosinusitis with nasal polyps https:\/\/clinicaltrials.gov\/show\/nct02170337"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0116|cit116","unstructured":"Study to evaluate multiple doses in patients with nasal polyposis https:\/\/clinicaltrials.gov\/show\/NCT02734849"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0117|cit117","unstructured":"Study of PF-06817024 in healthy subjects, in patients with chronic rhinosinusitis with nasal polyps and in patients with atopic dermatitis https:\/\/clinicaltrials.gov\/show\/NCT02743871 2016"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0118|cit118","unstructured":"Oral ifetroban to treat aspirin exacerbated respiratory disease (AERD) https:\/\/clinicaltrials.gov\/show\/nct03028350"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0119|cit119","unstructured":"Study of efficacy of fevipiprant in patients with nasal polyposis and asthma https:\/\/clinicaltrials.gov\/show\/nct03681093"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0120|cit120","unstructured":"A study to evaluate the effect of ACT-774312 in subjects with bilateral nasal polyposis https:\/\/clinicaltrials.gov\/show\/nct03688555"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0121|cit121","unstructured":"GB001 in adult subjects with chronic rhinosinusitis https:\/\/clinicaltrials.gov\/show\/nct03956862"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013513.pub3-BIB0122|cit122","first-page":"91","article-title":"Reslizumab decreases nasal adverse events and upper respiratory-associated concomitant medication use in patients with eosinophilic asthma and nasal polyps","volume":"73","author":"Perez De Llano","year":"2018","journal-title":"Allergy"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.anai.2013.01.024","article-title":"Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma","volume":"110","author":"Tajiri","year":"2013","journal-title":"Annals of Allergy, Asthma, & Immunology"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/ejo.ejo_19_19","article-title":"Anti-immunoglobulin E therapy: is it a valid option for the management of chronic rhinosinusitis with nasal polyposis?","volume":"35","author":"Wahba","year":"2019","journal-title":"Egyptian Journal of Otolaryngology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013513.pub3-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"AB12","DOI":"10.1016\/j.jaci.2017.12.038","article-title":"Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled Analysis of the SIROCCO and CALIMA Trials","volume":"73","author":"Zangrilli","year":"2019","journal-title":"Pneumologie (Stuttgart, Germany)"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0126|cit126","unstructured":"Gevaert P van Cauwenberge P Bachert C Future therapeutic possibilities: from anti-IL5 therapy onwards 3rd International Consensus Conference on Nasal Polyposis; 2004 Apr 23-25; Brussels, Belgium 2004"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.anai.2019.08.344","article-title":"Dupilumab a human anti-interleukin-4 receptor alpha monoclonal antibody for uncontrolled chronic rhinosinusitis with nasal polyps","volume":"123","author":"Nsouli","year":"2019","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0128|cit128","unstructured":"Aggravated airway inflammation: research on biological treatment (mepolizumab) AirGOs-biologics https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000421-76"},{"issue":"Suppl 106","key":"10.1002\/14651858.CD013513.pub3-BIB0129|cit129","first-page":"889","article-title":"NAPPREB study protocol: a pivotal clinical trial to investigate clinical efficacy and potential response biomarkers to benralizumab treatment in chronic rhinosinusitis with nasal polyps","volume":"74","author":"Heffler","year":"2019","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0130|cit130","unstructured":"Nasal polyps: inflammatory & molecular phenotyping of responders to benralizumab https:\/\/clinicaltrials.gov\/show\/NCT04185012"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0131|cit131","unstructured":"Study of benralizumab (KHK4563) in patients with eosinophilic chronic rhinosinusitis https:\/\/clinicaltrials.gov\/show\/NCT02772419"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0132|cit132","unstructured":"Effect of reslizumab in chronic rhinosinusitis https:\/\/clinicaltrials.gov\/show\/NCT02799446"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0133|cit133","unstructured":"Benralizumab effect on severe chronic rhinosinusitis with eosinophilic polyposis https:\/\/clinicaltrials.gov\/show\/nct03450083"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0134|cit134","unstructured":"Etokimab in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) https:\/\/clinicaltrials.gov\/show\/NCT03614923"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0135|cit135","unstructured":"Efficacy of dupilumab for patients with chronic rhinosinusitis without nasal polyps (CRSsNP) https:\/\/clinicaltrials.gov\/show\/NCT04362501"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0136|cit136","unstructured":"Dupilumab severe eosinophilic chronic sinusitis without nasal polyposis https:\/\/clinicaltrials.gov\/show\/NCT04430179"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0137|cit137","unstructured":"Efficacy and safety study of benralizumab in patient with eosinophilic chronic rhinosinusitis with nasal polyps (ORCHID) https:\/\/clinicaltrials.gov\/show\/NCT04157335"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0138|cit138","unstructured":"A multicentre, randomised, double-blind, parallel-group, placebo- controlled phase 3 efficacy and safety study of benralizumab in patients with eosinophilic chronic rhinosinusitis with nasal polyps (ORCHID) http:\/\/www.thaiclinicaltrials.org\/export\/pdf\/pdf.php?RID=3855"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0139|cit139","unstructured":"Efficacy and safety study of benralizumab for patients with severe nasal polyposis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-003675-61\/BE"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0140|cit140","unstructured":"Efficacy and safety study of benralizumab for patients with severe nasal polyposis https:\/\/clinicaltrials.gov\/show\/NCT03401229"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0141|cit141","unstructured":"Effect of mepolizumab in severe bilateral nasal polyps https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004255-70\/SE"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0142|cit142","unstructured":"Effect of mepolizumab in severe bilateral nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT03085797"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2011.12.002","article-title":"Age-related differences in the pathogenesis of chronic rhinosinusitis","volume":"129","author":"Cho","year":"2012","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011996.pub2","article-title":"Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis","author":"Chong","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0145|cit145","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011995.pub2","article-title":"Saline irrigation for chronic rhinosinusitis","author":"Chong","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0146|cit146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011993.pub2","article-title":"Different types of intranasal steroids for chronic rhinosinusitis","author":"Chong","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.anai.2019.07.004","article-title":"A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps","volume":"123","author":"Codispoti","year":"2019","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.otc.2011.03.005","article-title":"Nasal polyps: pathogenesis and treatment implications","volume":"44","author":"DeMarcantonio","year":"2011","journal-title":"Otolaryngologic Clinics of North America"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1398-9995.2009.01986.x","article-title":"Endothelial L-selectin ligand expression in nasal polyps","volume":"65","author":"Ebbens","year":"2010","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4193\/Rhino10.211","article-title":"Predictors of post-operative response to treatment: a double blind placebo controlled study in chronic rhinosinusitis patients","volume":"49","author":"Ebbens","year":"2011","journal-title":"Rhinology"},{"issue":"7109","key":"10.1002\/14651858.CD013513.pub3-BIB0151|cit151","first-page":"629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0152|cit152","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2007","volume":"45 Suppl 20","author":"Fokkens","year":"2007","journal-title":"Rhinology. Supplement"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0153|cit153","first-page":"1-298","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2012","volume":"50 Suppl 23","author":"Fokkens","year":"2012","journal-title":"Rhinology. Supplement"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0154|cit154","unstructured":"A multicentre, randomised, double-blind, parallel-group, placebo-controlled phase 3 efficacy and safety study of benralizumab for the prevention of recurrence of nasal polyps following surgical removal in patients with chronic rhinosinusitis with nasal polyps (OXALIS) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000195-38\/HU"},{"issue":"9","key":"10.1002\/14651858.CD013513.pub3-BIB0155|cit155","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub3","article-title":"Anti-IL5 therapies for asthma","author":"Farne","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0156|cit156","unstructured":"CFR - Code of Federal Regulations Title 21 https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=312.32"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0194-59989570152-4","article-title":"The health impact of chronic sinusitis in patients seeking otolaryngologic care","volume":"113","author":"Gliklich","year":"1995","journal-title":"Otolaryngology - Head and Neck Surgery"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0158|cit158","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0159|cit159","doi-asserted-by":"crossref","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions\u00a0version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"9","key":"10.1002\/14651858.CD013513.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1398-9995.2011.02646.x","article-title":"Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study","volume":"66","author":"Hastan","year":"2011","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0161|cit161","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011991.pub2","article-title":"Short-course oral steroids alone for chronic rhinosinusitis","author":"Head","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0162|cit162","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011992.pub2","article-title":"Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis","author":"Head","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0163|cit163","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011994.pub2","article-title":"Systemic and topical antibiotics for chronic rhinosinusitis","author":"Head","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013513.pub3-BIB0164|cit164","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012453.pub2","article-title":"Topical and systemic antifungal therapy for chronic rhinosinusitis","author":"Head","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub3-BIB0165|cit165","first-page":"110","article-title":"Responsiveness and minimal\u00a0clinically\u00a0important\u00a0difference\u00a0for the\u00a0EQ-5D\u00a0in chronic rhinosinusitis","volume":"57","author":"Hoehle","year":"2019","journal-title":"Rhinology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13643-015-0157-5","article-title":"Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review","volume":"4","author":"Hong","year":"2015","journal-title":"Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clinical Otolaryngology"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4193\/Rhin17.247","article-title":"CHronic Rhinosinusitis Outcome MEasures (CHROME), developing a core outcome set for trials of interventions in chronic rhinosinusitis","volume":"56","author":"Hopkins","year":"2018","journal-title":"Rhinology"},{"issue":"2","key":"10.1002\/14651858.CD013513.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/alr.22473","article-title":"The role of biologics in chronic rhinosinusitis: a systematic review","volume":"10","author":"Iqbal","year":"2020","journal-title":"International Forum of Allergy & Rhinology"},{"issue":"6","key":"10.1002\/14651858.CD013513.pub3-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/bmjebm-2018-110963","article-title":"When to include clinical study reports and regulatory documents in systematic reviews","volume":"23","author":"Jefferson","year":"2018","journal-title":"BMJ Evidence-Based Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/1744666X.2019.1541738","article-title":"Chronic rhinosinusitis with nasal polyps: insights into mechanisms of disease from emerging biological therapies","volume":"15","author":"Kariyawasam","year":"2019","journal-title":"Expert Review of Clinical Immunology"},{"issue":"6","key":"10.1002\/14651858.CD013513.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2500\/ajr.2008.22.3228","article-title":"Perspectives on the etiology of chronic rhinosinusitis: an immune barrier hypothesis","volume":"22","author":"Kern","year":"2008","journal-title":"American Journal of Rhinology"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1398-9995.2011.02706.x","article-title":"Differential expression of interleukin-32 in chronic rhinosinusitis with and without nasal polyps","volume":"67","author":"Keswani","year":"2012","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2019.12.001","article-title":"Biologics in chronic rhinosinusitis with nasal polyposis","volume":"124","author":"Laidlaw","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00005537-200404000-00022","article-title":"Origin of nasal polyps: an endoscopic autopsy study","volume":"114","author":"Larsen","year":"2004","journal-title":"Laryngoscope"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0176|cit176","unstructured":"Dupilumab in CRSsNP https:\/\/clinicaltrials.gov\/show\/NCT04678856"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0178|cit178","unstructured":"McDonald S Noel-Storr AH Thomas J Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews Global Evidence Summit; 2017 Sep 13-17; Cape Town, South Africa 2017"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0179|cit179","unstructured":"Dupilumab for prevention of recurrence of CRSwNP after ESS https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04596189"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0180|cit180","unstructured":"Efficacy and safety of mepolizumab in adults with chronic rhinosinusitis with nasal polyps (CRSwNP)\/eosinophilic chronic rhinosinusitis (ERCS) (MERIT) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04607005"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0181|cit181","unstructured":"A study assessing the efficacy and safety of CBP-201 in adult patients with chronic rhinosinusitis with nasal polyps https:\/\/clinicaltrials.gov\/show\/NCT04783389"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0182|cit182","unstructured":"Subcutaneously CM310\/placebo in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) https:\/\/clinicaltrials.gov\/show\/NCT04805398"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0183|cit183","unstructured":"Aggravated airway inflammation: research on biological treatment (mepolizumab) https:\/\/clinicaltrials.gov\/show\/NCT04823585"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0184|cit184","unstructured":"National Institute for Health and Care Excellence (NICE) Omalizumab for treating chronic rhinosinusitis with nasal polyps ID1650 https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10558"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0185|cit185","unstructured":"Noel-Storr AH The Project Transform Team Cochrane Crowd: new ways of working together to produce health evidence Evidence Live; 2018 Jun 18-20; Oxford, UK 2018"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013513.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.anai.2020.08.167","article-title":"Reslizumab an interleukin-5 antagonist monoclonal antibody for uncontrolled chronic rhinosinusitis with nasal polyps","volume":"125","author":"Nsouli","year":"2020","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"e006680","DOI":"10.1136\/bmjopen-2014-006680","article-title":"The burden of revision sinonasal surgery in the UK\u2014data from the Chronic Rhinosinusitis Epidemiology Study (CRES): a cross-sectional study","volume":"5","author":"Philpott","year":"2015","journal-title":"BMJ Open"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00005537-200405000-00027","article-title":"Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomised, controlled trial","volume":"114","author":"Ragab","year":"2004","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1002\/14651858.CD013513.pub3-BIB0189|cit189","first-page":"305","article-title":"Impact of chronic rhinosinusitis therapy on quality of life: a prospective randomized controlled trial","volume":"48","author":"Ragab","year":"2010","journal-title":"Rhinology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0190|cit190","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2019"},{"issue":"11","key":"10.1002\/14651858.CD013513.pub3-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1177\/0003489417731782","article-title":"Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis","volume":"126","author":"Rivero","year":"2017","journal-title":"Annals of Otology, Rhinology, and Laryngology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jclinepi.2017.08.008","article-title":"Living systematic reviews: 3. Statistical methods for updating meta-analyses","volume":"91","author":"Simmonds","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1945892418787132","article-title":"Biologics in chronic rhinosinusitis: an update and thoughts for future directions","volume":"32","author":"Smith","year":"2018","journal-title":"American Journal of Rhinology & Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/alr.22264","article-title":"Long-term revision rates for endoscopic sinus surgery","volume":"9","author":"Smith","year":"2019","journal-title":"International Forum of Allergy & Rhinology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0196|cit196","unstructured":"Takabayashi T Asaka D Okamoto Y Himi T Haruna S Yoshida N A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-il-5r alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis American Journal of Rhinology & Allergy"},{"issue":"6","key":"10.1002\/14651858.CD013513.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaci.2011.08.037","article-title":"Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps","volume":"128","author":"Tan","year":"2011","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jclinepi.2017.08.011","article-title":"Living systematic reviews 2: combining human and machine effort","volume":"91","author":"Thomas","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1513\/pats.201005-036RN","article-title":"Pathophysiology of chronic rhinosinusitis","volume":"8","author":"Tomassen","year":"2011","journal-title":"Proceedings of the American Thoracic Society"},{"issue":"1","key":"10.1002\/14651858.CD013513.pub3-BIB0200|cit200","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4193\/Rhin17.156","article-title":"Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review","volume":"56","author":"Tsetsos","year":"2018","journal-title":"Rhinology"},{"issue":"7","key":"10.1002\/14651858.CD013513.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/alr.22576","article-title":"Effect of monoclonal antibodies on olfactory dysfunction caused by chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis","volume":"10","author":"Tsetsos","year":"2020","journal-title":"International Forum of Allergy & Rhinology"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0202|cit202","unstructured":"Tversky J Lane AP Azar A Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial Clinical and Experimental Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013513.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.iac.2009.07.003","article-title":"Inflammation in chronic rhinosinusitis and nasal polyposis","volume":"29","author":"Drunen","year":"2009","journal-title":"Immunology and Allergy Clinics of North America"},{"issue":"6","key":"10.1002\/14651858.CD013513.pub3-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/jamia\/ocx053","article-title":"Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach","volume":"24","author":"Wallace","year":"2017","journal-title":"Journal of the American Medical Informatics Association"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0205|cit205","unstructured":"Walter S Ho J Alvarado R Rimmer J Campbell R Kalish L Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: a systematic review Clinical and Experimental Allergy 10.1111\/cea.13721 32808380"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0206|cit206","unstructured":"Efficacy and safety of tezepelumab in participants with severe chronic rhinosinusitis with nasal polyposis https:\/\/clinicaltrials.gov\/show\/NCT04851964"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaci.2008.07.008","article-title":"Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease","volume":"122","author":"Zhang","year":"2008","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013513.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2222.2008.03198.x","article-title":"Chronic rhinosinusitis with and without nasal polyps is associated with decreased expression of glucocorticoid-induced leucine zipper","volume":"39","author":"Zhang","year":"2009","journal-title":"Clinical and Experimental Allergy"},{"issue":"12","key":"10.1002\/14651858.CD013513.pub3-BIB0209|cit209","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013513","article-title":"Biologics for chronic rhinosinusitis","author":"Chong","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013513.pub3-BIB0210|cit210","unstructured":"Biologics for chronic rhinosinusitis Cochrane Database of Systematic Reviews 2020 2 CD013513 10.1002\/14651858.CD013513.pub2"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:32:54Z","timestamp":1791433974000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013513.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane ENT Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":210,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013513.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]}}}